Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS002 in Primary Hypercholesterolaemia and Mixed Dyslipidemia
NCT05621070Phase 3Recruiting
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Feb 2023
- Primary completion
- Sep 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ongericimab in hypercholesterolemia and mixed dyslipidemia (4 arms), sponsored by Shanghai Junshi Biosciences Co., Ltd. Primary endpoint: Percent Change From Baseline in LDL-C at 12 weeks. Started Feb 2023; status: recruiting.
02
Drugs
ongericimab
03
Conditions
hypercholesterolemiamixed dyslipidemia
Beyond the preview
Go deeper on NCT05621070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05621070.